Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Omisirge Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The historic growth was driven by several key factors, including a rising number of hematologic malignancy cases, the shortcomings associated with standard cord blood transplantation, promising early clinical outcomes from cell expansion methods, a higher adoption rate of allogeneic stem cell transplants, and regulatory endorsements for sophisticated cell therapy products.
The expansion of personalized cell therapy pipelines, increased funding for regenerative medicine, broader implementation of sophisticated transplantation protocols, heightened emphasis on minimizing complications following transplants, and the growth of manufacturing facilities for cell therapy are driving growth in the forecast period. Key trends during this period comprise the greater utilization of expanded cord blood treatments, a surge in ex vivo cell expansion methods, an intensified focus on achieving quicker neutrophil engraftment, the widening scope of allogeneic hematopoietic stem cell transplantation (HSCT) applications, and improved scalability in the production of cell therapies.
Download A Free Sample Report For Comprehensive Market Insights:
Omisirge Market Development Factors: Which Trends Are Supporting Demand?
The rising demand for personalized medical approaches is anticipated to fuel the expansion of the omisirge market in the years ahead. These treatments refer to healthcare strategies customized according to a person’s distinct genetic makeup, environment, and lifestyle choices, designed to boost effectiveness and reduce adverse effects. This growing preference for individualized medicine stems from progress in genetic research, heightened public awareness of tailored healthcare, and a broader understanding that such therapies deliver better results and fewer complications than conventional uniform methods. Omisirge supports individualized care by adjusting itself to each patient’s specific requirements, targeting particular immune reactions, and improving therapeutic success based on the distinct traits of a patient’s cancer. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the United States, reported that the FDA cleared 16 new personalized therapies for those with rare diseases in 2023, a notable jump from just six approvals in 2022. As a result, the increasing demand for customized treatments is set to drive the growth of the omisirge market.
Omisirge Market Segment Landscape: Which Areas Lead Market Development?
The omisirge market covered in this report is segmented –
1) By Clinical Indication: Leukemia, Lymphoma, Myeloma, Other Hematologic Malignancies
2) By Distribution Channel: Direct Sales, Distributors
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers
Omisirge Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the Omisirge market are prioritizing technological innovation, particularly through the development of omidubicel-onlv, to boost transplant effectiveness and accelerate patient recovery. Omidubicel-onlv represents an allogeneic stem-cell therapy sourced from umbilical cord blood, specifically engineered to promote cell expansion and facilitate quicker engraftment. A notable example occurred in May 2023, when the U.S. Food and Drug Administration, a federal agency based in the United States, granted approval to Gamida Cell’s product Omisirge. This therapy is designed to enhance stem cell engraftment and minimize infection risks for transplant recipients. With this FDA approval, Omisirge introduced an advanced, expanded cell therapy derived from cord blood, aimed at speeding up neutrophil recovery and reducing infection rates in patients with hematologic malignancies. Compared to conventional cord blood, it provides a more dependable engraftment profile, resulting in faster and clinically safer transplant procedures.
Omisirge Market Industry Leaders And Market Competition
Major companies operating in the omisirge market are Gamida Cell Ltd.
Access The Complete Omisirge Market Report:
Omisirge Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the omisirge market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omisirge market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model